What happened with TCRX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
TScan Therapeutics engineers patient or donor T cells with receptors intended to recognize cancer targets. Its development focus is blood cancers. Its lead treatment candidate, TSC-101, is in clinical testing for people with acute myeloid leukemia or myelodysplastic syndromes who receive a donor stem-cell transplant. It is designed to eliminate remaining disease and prevent relapse. TScan manufactures cells for its clinical programs in-house.
Amgen supplies the company's disclosed collaboration revenue, paying TScan to identify targets recognized by T cells in Crohn's disease. Amgen holds global rights to develop and commercialize treatments from that collaboration. TScan has received an upfront payment and is eligible for payments tied to development and commercial milestones, plus royalties if collaboration products reach the market.
TScan has no approved therapies and has never earned revenue from product sales. It cannot market its treatment candidates without regulatory approval. Turning its cancer research into a medicine business depends on demonstrating safety and effectiveness in trials and establishing reliable manufacturing. For now, it funds operations through share sales, collaboration payments and debt, and needs additional capital to continue development.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
TScan’s prospects hinge on post-transplant AML and MDS trial results and financing, with private BlueSphere Bio and Orca Biosystems also worth watching as competitors to its lead program.
Marker Therapeutics overlaps directly with TScan’s lead TSC-101 program: its MT-401-OTS uses donor T cells to treat AML and MDS, the diseases TScan targets after transplant. Watch MT-401-OTS trial results as a competing approach that expands naturally occurring cancer-targeting cells without genetic modification.
Immatics competes with TScan by engineering T cells to recognize cancer targets inside cells, including PRAME, in patients with matching immune-system markers called HLA. Its PRAME cell-therapy results offer a comparison for TScan’s solid-tumor work, though TScan paused further enrollment in that trial to prioritize blood cancers.
Amgen pays TScan to identify targets recognized by T cells in Crohn’s disease and keeps worldwide rights to develop and sell resulting treatments; this agreement accounts for TScan’s disclosed collaboration revenue. Watch progress in that research rather than Amgen’s medicine sales: TScan’s revenue from the agreement rose from $2.8 million in 2024 to $10.3 million in 2025, mainly because of research timing.
Immunocore competes with TScan for cancer targets displayed on cell surfaces by HLA, but uses soluble receptor medicines rather than engineered T cells. Sales and adoption of its approved KIMMTRAK treatment for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma show commercial uptake of that alternative approach, not results in TScan’s lead patient group.
Allogene and TScan both develop engineered donor T cells for cancer, so safety, efficacy and manufacturing results are relevant to both, although Allogene’s ready-made treatments differ from TScan’s post-transplant AML and MDS approach. Watch Allogene’s ALPHA3, RESOLUTION and TRAVERSE programs for progress in making donor-cell treatments work reliably.
Caribou’s donor-cell trial results can inform TScan holders about safety, persistence and efficacy in blood cancers, but its CAR-T treatments target lymphoma and myeloma rather than TScan’s TCR-T approach for AML and MDS. Watch vispa-cel in relapsed or refractory B-cell non-Hodgkin lymphoma and CB-011 in relapsed or refractory multiple myeloma.
Amgen Inc earningsAMGN
Amgen pays TScan to research targets in Crohn’s disease and retains worldwide development and sales rights; Amgen’s report can show how the collaboration’s research is progressing and how it feeds into TScan’s revenue.
Look for Amgen’s updates on the collaborative research, then compare them with TScan’s collaboration and license revenue. More research progress alongside higher revenue recognized by TScan would show the agreement contributed more income in the period; lower revenue may reflect the timing of research activity and does not by itself show weaker Amgen drug sales or weaker research.
TScan Therapeutics, Inc. earningsThis company
TScan Therapeutics has no approved therapies and relies mainly on collaboration revenue from Amgen; this report will show whether that research income is keeping pace with the cost of developing therapies.
Read collaboration and license revenue alongside operating expenses. Rising collaboration revenue with contained expense growth would mean research work is covering more of development costs; falling revenue or rising expenses would mean TScan still relies mainly on cash to fill the gap, making the cash runway more important.
Marker Therapeutics, Inc. earningsMRKR
Marker Therapeutics’ report will show progress in its MT-401-OTS trials for AML and MDS, the same post-transplant blood cancers targeted by TScan’s TSC-101.
Look at MT-401-OTS trial results in AML and MDS, and whether they support this donor T-cell approach, which does not genetically modify the cells. Strong results would show TSC-101 faces a more direct competitor in the same diseases; weak results or delays would mean less competitive pressure from this alternative.
